Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press88410.17650/2949-5857-2025-15-4-11-18LITERATURE REVIEWОБЗОР ЛИТЕРАТУРЫReview ArticleNew drugs in the 2nd line of therapy of small cell lung cancerНовые препараты 2-й линии терапии мелкоклеточного рака легкогоhttps://orcid.org/0000-0002-5441-8424SeydinovichA.СейдиновичА.
Russian Federation
alen-s-99@yandex.ruhttps://orcid.org/0000-0002-1357-0956KuzminovA. E.КузьминовА. Е.
Russian Federation
alen-s-99@yandex.ruhttps://orcid.org/0000-0002-4548-1026BarbolinaT. D.БарболинаТ. Д.
Russian Federation
alen-s-99@yandex.ruhttps://orcid.org/0000-0002-0042-1150Ter-OvanesovM. D.Тер-ОванесовМ. Д.
Russian Federation
alen-s-99@yandex.ruhttps://orcid.org/0000-0002-6244-4294BrederV. V.БредерВ. В.
Russian Federation
alen-s-99@yandex.ruhttps://orcid.org/0000-0003-4469-502XLaktionovK. K.ЛактионовК. К.
Russian Federation
alen-s-99@yandex.ruN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииN.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииRussian University of Medicine, Ministry of Health of RussiaФГБОУ ВО «Российский университет медицины» Минздрава России2112202515411182112202521122025Copyright ©; 2025, ABV-pressCopyright ©; 2025, АБВ-пресс2025ABV-pressАБВ-прессhttps://onco-surgery.info/jour/about/editorialPolicieshttps://onco-surgery.info/jour/article/view/884

Small cell lung cancer (SCLC) is the most aggressive histological subtype of lung cancer and accounts for approximately 13–15 % of all lung cancers. The aggressive nature of SCLC is manifested through rapid progression of the disease accompanied by early metastases. Despite good response to chemotherapy, recurrences and progression quickly develop requiring switching to the second line of chemotherapy, efficacy of which remains very low. As a result, the purpose of our publication is to review data on the standard therapy schemes, as well as new drugs used in the second line of SCLC therapy, namely lurbinectedin and tarlatamab. The review contains literature sources on the research on these drugs from the PubMed database published between 2015 and 2024.

Мелкоклеточный рак легкого (МРЛ) является наиболее агрессивным гистологическим подтипом рака легкого и составляет примерно 13–15 % всех его случаев. Агрессивный характер МРЛ проявляется в быстром прогрессировании заболевания, сопровождающемся ранним метастазированием. Несмотря на хороший ответ на химиотерапию, у пациентов быстро развиваются рецидив и прогрессирование, что требует назначения 2-й линии химиотерапии, эффективность которой остается весьма низкой. В связи с этим целью работы стал обзор данных литературы о стандартных схемах лечения, а также о новых препаратах, используемых во 2-й линии терапии МРЛ, а именно лурбинектедине и тарлатамабе. Обзор включает публикации из базы PubMed за 2015–2024 гг., посвященные данным препаратам.

small cell lung cancersecond linelurbinectedintarlatamabмелкоклеточный рак легкого2-я линия терапиилурбинектединтарлатамабSolta A., Ernhofer B., Boettiger K. et al. Small cells – big issues: biological implications and preclinical advancements in small cell lung cancer. Mol Cancer 2024;1(23):41. DOI: 10.1186/s12943-024-01953-9Fedyanin M.Yu. Elsnukaeva Kh.Kh.-M., Tryakin A.A., Tyulyandin S.A. Some aspects of immunotherapy in colon cancer. Onkologicheskaya koloproktologiya = Colorectal Oncology 2018;1(8):19–27. DOI: 10.17650/2220-3478-2018-8-1-19-27Федянин М.Ю., Эльснукаева Х.Х.-М., Трякин А.А., Тюляндин С.А. Некоторые аспекты иммунотерапии при раке толстой кишки. Онкологическая колопроктология 2018;8(1):19–27. DOI: 10.17650/2220-3478-2018-8-1-19-27Badin F. Considerations for selecting second-line treatment in patients with progressive small cell lung cancer and the use of Lurbinectedin in this setting. Cancer Treat Res Commun 2024;39:100803. DOI: 10.1016/j.ctarc.2024.100803Paz-Ares L., Champiat S., Lai W.V. et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study. J Clin Oncol 2023;16(41):2893–903. DOI: 10.1200/JCO.22.02823Belitsky G.A., Kirsanov K.I., Lesovaya E.A., Yakubovskaya M.G. Trabectedin – the DNA minor groove binder. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2015;2(2):41–9. (In Russ.). DOI: 10.17650/2313-805X.2015.2.2.41-49Белицкий Г.А., Кирсанов К.И., Лесовая Е.А., Якубовская М.Г. Трабектедин – лиганд узкой бороздки ДНК. Успехи молекулярной онкологии 2015;2(2):41–9. DOI: 10.17650/2313-805X.2015.2.2.41-49Fedenko A.A., Tararykova A.A. Trabectedin in the treatment of soft tissue sarcomas: up to date data. Sarkomy kostey, myagkikh tkaney i opukholi kozhi = Bone and Soft Tissue Sarcomas, Tumors of the Skin 2021;3(13):16–27. DOI: 10.17650/2782-3687-2021-13-3-16-27Феденко А.А., Тарарыкова А.А. Роль трабектедина в лечении сарком мягких тканей: обзор современных данных. Саркомы костей, мягких тканей и опухоли кожи 2021;13(3):16–27. DOI: 10.17650/2782-3687-2021-13-3-16-27Farago A.F., Drapkin B.J., Lopez-Vilarino de Ramos J.A. et al. ATLANTIS: a phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. Future Oncol 2019;3(15):231–9. DOI: 10.2217/fon-2018-0597Gadducci A., Cosio S. Trabectedin and lurbinectedin: mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma. Front Oncol 2022;(12):914342. DOI: 10.3389/fonc.2022.914342Trigo J., Subbiah V., Besse B. et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol 2020;5(21):645–54. DOI: 10.1016/S1470-2045(20)30676-8Shinn L.T., Vo K.A., Reeves D.J. Lurbinectedin: a new treatment option for relapsed/refractory small-cell lung cancer. Ann Pharmacother 2021;9(55):1172–9. DOI: 10.1177/1060028020983014Subbiah V., Paz-Ares L., Besse B. et al. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer 2020;150:90–6. DOI: 10.1016/j.lungcan.2020.10.003Desai A., Smith C.J., Ashara Y. et al. Real-world outcomes with lurbinectedin in second-line setting and beyond for extensive stage small cell lung cancer. Clin Lung Cancer 2023;8(24):689–95.e1. DOI: 10.1016/j.cllc.2023.09.001Baize N., Monnet I., Greillier L. et al. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2020;21(9):1224–33. DOI: 10.1016/s1470-2045(20)30461-7Goto K., Ohe Y., Shibata T. et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2016;17(8):1147–57. DOI: 10.1016/S1470-2045(16)30104-8O’Brien M.E., Ciuleanu T.E., Tsekov H. et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24(34):5441–7. DOI: 10.1200/jco.2006.06.5821Eckardt J.R., von Pawel J., Pujol J.L. et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25(15):2086–92. DOI: 10.1200/jco.2006.08.3998European Medicines Agency. Scientific Discussion: Hycamtin. 2006. Available at: https://www.ema.europa.eu/en/documents/scientific-discussion-variation/hycamtin-h-c-123-ii-0034-epar-scientific-discussion-variation_en.pdfVon Pawel J., Schiller J.H., Shepherd F.A. et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17(2):658–67. DOI: 10.1200/jco.1999.17.2.658Von Pawel J., Jotte R., Spigel D.R. et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 2014;32(35):4012–9. DOI: 10.1200/jco.2013.54.5392Ardizzoni A., Hansen H., Dombernowsky P. et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European organization for research and treatment of cancer early clinical studies group and new drug development office, and the lung cancer cooperative group. J Clin Oncol 1997;15(5):2090–6. DOI: 10.1200/JCO.1997.15.5.2090Inoue A., Sugawara S., Maemondo M. et al. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: north Japan lung cancer study group trial 0702. Lung Cancer 2015;89(1):61–5. DOI: 10.1016/j.lungcan.2015.04.012Aix S.P., Navarro A., Bernabé R. et al. 464 2SMALL (NCT04253145) phase I part: lurbinectidine (LUR) in combination with atezolizumab (ATZ) for second line extensive stage small cell lung cancer (ES-SCLC) patients (pts). J Immunother Cancer 2021;9(Suppl 2):A493. DOI: 10.1136/jitc-2021-SITC2021.464Morgensztern D., Besse B., Greillier L. et al. Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase II TRINITY study. Clin Cancer Res 2019;23(25):6958–66. DOI: 10.1158/1078-0432.CCR-19-1133Trillo Aliaga P., Del Signore E., Fuorivia V. et al. The evolving scenario of ES-SCLC management: from biology to new cancer therapeutics. Genes (Basel) 2024;15(6):701. DOI: 10.3390/genes15060701Deneka A.Y., Boumber Y., Beck T., Golemis E.A. Tumor-targeted drug conjugates as an emerging novel therapeutic approach in small cell lung cancer (SCLC). Cancers 2019;9(11):1297. DOI: 10.3390/cancers11091297Gray J.E., Heist R.S., Starodub A.N. et al. Therapy of small cell lung cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting Trop-2, sacituzumab govitecan. Clin Cancer Res 2017;19(23):5711–9. DOI: 10.1158/1078-0432Rudin C.M., Reck M., Johnson M.L. et al. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J Hematol Oncol 2023;16(1):66. DOI: 10.1186/s13045-023-01464-yPaz-Ares L.G., Felip E., Ahn M.-J. et al. Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304). J Clin Oncol 2023;41:TPS8611. DOI: 10.1200/JCO.2023.41.16_suppl.TPS8611